한글목차

세계의 금연 보조제 시장 규모는 2024년에 230억 2,000만 달러로 평가되었고, 2030년까지 연평균 복합 성장률(CAGR) 7.28%로 강력한 성장이 예측되고 있습니다.

이 시장은 헬스케어의 중요한 부분이며 다양한 제품 및 서비스를 통해 금연을 지원하는 데 초점을 맞추었습니다. 담배 사용에 따른 건강 위험에 대한 인식이 높아짐에 따라 금연 보조제의 채택이 증가하고 있습니다. 시장에는 니코틴 대체 요법(NRT), 처방약, 전자 담배, 디지털 개입이 포함됩니다. 독일 최초 제네릭 니코틴 튜잉엄과 같은 혁신적인 솔루션 도입과 Achieve Life Sciences사의 ORCA-V1 시험과 같은 유망한 임상 결과는 이용하기 쉽고 효과적인 금연 보조제가 중시되고 있음을 뒷받침합니다. 기술의 진보와 소비자의 건강 의식의 고조가 개별화된 치료법의 개발과 보급을 뒷받침하고 있어 시장은 향후 몇 년간 꾸준히 확대될 것으로 보입니다.

시장 성장 촉진요인

건강에 대한 의식 증가

주요 시장 과제

효능 인식 및 안전에 대한 우려

주요 시장 동향

디지털 금연 솔루션의 상승

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 금연 보조제 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율 및 예측
  • 제품별(니코틴 대체요법, 의약품, 전자 담배, 기타)
  • 최종 사용자별(병원 약국, 온라인 채널, 소매 약국, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 금연 보조제 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 금연 보조제 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 금연 보조제 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 금연 보조제 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 금연 보조제 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향 및 발전

• 최근 동향
• 제품 출시
• 합병 및 인수

제13장 세계의 금연 보조제 시장 : SWOT 분석

제14장 경쟁 구도

• Pfizer Inc.
• GlaxoSmithKline PLC
• Hoffmann-La Roche AG
• Novartis AG
• Johnson and Johnson
• Bayer AG
• Cipla Ltd
• Takeda Pharmaceuticals Co. Ltd
• British American Tobacco PLC
• Kimree Technology Inc
• Imperial Tobacco Ltd

제15장 전략적 제안

제16장 기업 소개 및 면책사항

영문목차

The Global Smoking Cessation Aids Market was valued at USD 23.02 billion in 2024 and is projected to witness robust growth at a CAGR of 7.28% through 2030. This market is a vital part of the healthcare landscape, focused on helping individuals quit smoking through a range of products and services. As awareness of the health risks associated with tobacco use increases, there is rising adoption of smoking cessation aids. The market includes nicotine replacement therapies (NRT), prescription medications, electronic cigarettes, and digital interventions. The introduction of innovative solutions, such as Germany's first generic nicotine chewing gum and promising clinical results from trials like Achieve Life Sciences' ORCA-V1 study, underscores the growing emphasis on accessible and effective quit-smoking aids. Technological advances and growing consumer health consciousness are driving the development and uptake of personalized treatment options, positioning the market for steady expansion in the coming years.

Key Market Drivers

Rising Awareness and Health Concerns

Increasing awareness of the health hazards linked to tobacco use is a major factor propelling the global smoking cessation aids market. Public understanding of the correlation between smoking and life-threatening diseases-such as cardiovascular disorders, respiratory illnesses, and cancers-has significantly grown, motivating individuals to seek out cessation support. Furthermore, the global emphasis on personal health and well-being is encouraging more people to take proactive steps toward quitting. As individuals prioritize longevity and a higher quality of life, demand for effective, science-backed smoking cessation products continues to rise. This heightened health consciousness is translating into increased usage of both over-the-counter and prescribed quit-smoking aids.

Key Market Challenges

Perceived Effectiveness and Safety Concerns

A notable challenge in the smoking cessation aids market is public skepticism surrounding the effectiveness and safety of available products. Some consumers doubt whether these aids genuinely improve quit rates or worry about potential side effects, particularly with pharmaceutical interventions. This hesitation can discourage individuals from using cessation aids altogether, opting instead for unsupported or self-guided attempts to quit. Addressing these concerns by reinforcing evidence-based outcomes and educating users on proper usage is critical for increasing adoption and trust in cessation therapies.

Key Market Trends

Rise in Digital Smoking Cessation Solutions

A growing trend in the smoking cessation landscape is the adoption of digital tools and services. Mobile apps, online coaching platforms, and telehealth services are becoming increasingly popular for their convenience, accessibility, and personalized features. These platforms offer real-time support, behavioral tracking, and adaptive quit plans that cater to individual needs. The integration of digital solutions reflects the broader shift in healthcare toward technology-driven interventions, opening new opportunities for engagement and treatment effectiveness in the smoking cessation market.

Key Market Players

• Pfizer Inc.
• GlaxoSmithKline PLC
• Hoffmann-La Roche AG
• Novartis AG
• Johnson and Johnson
• Bayer AG
• Cipla Ltd
• Takeda Pharmaceuticals Co. Ltd
• British American Tobacco PLC
• Kimree Technology Inc
• Imperial Tobacco Ltd

Report Scope:

In this report, the Global Smoking Cessation Aids Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Smoking Cessation Aids Market, By Product:

• Nicotine Replacement Therapy
• Drugs
• Electronic Cigarettes
• Others

Smoking Cessation Aids Market, By End-User:

• Hospital Pharmacies
• Online Channels
• Retail Pharmacies
• Other

Smoking Cessation Aids Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Smoking Cessation Aids Market.

Available Customizations:

Global Smoking Cessation Aids market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Smoking Cessation Aids Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Nicotine Replacement Therapy, Drugs, Electronic Cigarettes, Others)
  • 5.2.2. By End-User (Hospital Pharmacies, Online Channels, Retail Pharmacies, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Smoking Cessation Aids Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By End-User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Smoking Cessation Aids Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By End-User
  • 6.3.2. Canada Smoking Cessation Aids Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By End-User
  • 6.3.3. Mexico Smoking Cessation Aids Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By End-User

7. Europe Smoking Cessation Aids Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By End-User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Smoking Cessation Aids Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By End-User
  • 7.3.2. United Kingdom Smoking Cessation Aids Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By End-User
  • 7.3.3. Italy Smoking Cessation Aids Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By End-User
  • 7.3.4. France Smoking Cessation Aids Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By End-User
  • 7.3.5. Spain Smoking Cessation Aids Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By End-User

8. Asia-Pacific Smoking Cessation Aids Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By End-User
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Smoking Cessation Aids Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By End-User
  • 8.3.2. India Smoking Cessation Aids Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By End-User
  • 8.3.3. Japan Smoking Cessation Aids Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By End-User
  • 8.3.4. South Korea Smoking Cessation Aids Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By End-User
  • 8.3.5. Australia Smoking Cessation Aids Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By End-User

9. South America Smoking Cessation Aids Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By End-User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Smoking Cessation Aids Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By End-User
  • 9.3.2. Argentina Smoking Cessation Aids Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By End-User
  • 9.3.3. Colombia Smoking Cessation Aids Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By End-User

10. Middle East and Africa Smoking Cessation Aids Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By End-User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Smoking Cessation Aids Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By End-User
  • 10.3.2. Saudi Arabia Smoking Cessation Aids Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By End-User
  • 10.3.3. UAE Smoking Cessation Aids Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Smoking Cessation Aids Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Pfizer Inc.
  • 14.1.1. Business Overview
  • 14.1.2. End-User Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Key Personnel
  • 14.1.5. SWOT Analysis
• 14.2. GlaxoSmithKline PLC
• 14.3. Hoffmann-La Roche AG
• 14.4. Novartis AG
• 14.5. Johnson and Johnson
• 14.6. Bayer AG
• 14.7. Cipla Ltd
• 14.8. Takeda Pharmaceuticals Co. Ltd
• 14.9. British American Tobacco PLC
• 14.10. Kimree Technology Inc
• 14.11. Imperial Tobacco Ltd

15. Strategic Recommendations

16. About Us & Disclaimer